Cookson Peirce & Co. Inc. Purchases Shares of 2,877 Gilead Sciences, Inc. $GILD

Cookson Peirce & Co. Inc. purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 2,877 shares of the biopharmaceutical company’s stock, valued at approximately $319,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD raised its stake in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares during the last quarter. Nuveen LLC purchased a new stake in Gilead Sciences in the first quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC purchased a new position in shares of Gilead Sciences in the second quarter worth about $238,083,000. Los Angeles Capital Management LLC raised its stake in shares of Gilead Sciences by 422.6% in the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock worth $282,706,000 after purchasing an additional 2,040,261 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 1.7% in the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Down 0.6%

Gilead Sciences stock opened at $120.74 on Friday. The firm has a market cap of $149.82 billion, a price-to-earnings ratio of 24.05, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The business’s 50-day moving average price is $115.41 and its 200 day moving average price is $110.89. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.96 by $0.05. The firm had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the company earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $295,200.00. Following the sale, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. This trade represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the sale, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 71,500 shares of company stock valued at $8,281,540. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research analyst reports. Wolfe Research raised their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday. TD Cowen raised their price objective on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Finally, BMO Capital Markets raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.